Wolfe Research Upgrades Madrigal Pharmaceuticals to Outperform, Announces $605 Price Target
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsUpgradesPrice Target
Wolfe Research analyst Andy Chen upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from Peer Perform to Outperform and announces $605 price target.
Wolfe Research analyst Andy Chen upgrades Madrigal Pharmaceuticals (NASDAQ:MDGL) from Peer Perform to Outperform and announces $605 price target.